58results about How to "Cut wound" patented technology

The present invention provides a rotatable stapling head of a surgical stapler, which comprises a staple cartridge (1), a staple driver (2), a scalpel (3), a compression rod (4), a staple casing (5) and a rotating assembly. The above parts constitute a rotating forward mechanism which can rotatablely forward the scalpel therein.

A reduced-pressure, linear-wound closing bolster has a pivotable frame that moves from an extended position to a compressed position under the influence of reduced pressure. The closing bolster may have a first closing member, a second closing member, and an interior space. A manifold member is disposed within the interior space and may be coupled to the pivotable frame. When a reduced pressure is applied, the pivotable frame is urged from the extended position to the compressed position. A first gripping member for transmitting a closing force from the first closing member to a first edge of a linear wound may be attached. Likewise, a second gripping member for transmitting a closing force from the second closing member to a second edge of the linear wound may be attached. Systems and methods are also presented.

A medical device for example a wound dressing having antibacterial and optionally, antifungal properties, are provided together with methods for making the device. An exemplary dressing includes a layer of silver-containing fabric, (optionally) a layer of absorbent material, and (optionally) a layer of flexible air-permeable and / or water-impermeable material. The dressing can be used for prophylactic and therapeutic care and treatment of skin infections and surface wounds (including surgical incisions), as a packing material, and as a swab for surface cleaning.

Methods and devices for treatment of damaged tissue are disclosed, including treatment of wounds by employing non-electrically powered, reduced pressure therapy devices with a pressure oscillation mechanism. Maintenance and control of the sub atmospheric pressure exerted may be provided by such devices while minimizing discomfort to the user. The devices may be configured to be worn inconspicuously underneath clothing.

Wound fluid blood detection systems and methods are described that are operable in conjunction with reduced pressure wound treatment (RPWT) systems, as well as ancillary therapy and monitoring systems applied concurrently with RPWT systems. The blood detection monitor operates by optically characterizing the content of wound fluids to the extent of identifying percentage blood content. This identification relies upon the transmission of select wavelengths of light across a volume of wound fluid to a photo detector (connected to signal processing instrumentation) capable of quantifying the absorption characteristics of the fluid. The detection components may be implemented in conjunction with either a fluid flow conduit (i.e. the reduced pressure tubing directing fluid away from the wound dressing) or more directly in association with the materials that comprise the wound dressing positioned within the wound bed itself. In addition, the present invention is configured to operate in conjunction with blood gas monitoring systems operating with the RPWT. Finally, the components of the systems that serve to illuminate the wound bed, lend themselves to use in conjunction with illumination in discreet electromagnetic wave wavelengths suitable for the application of phototherapy.

A method of conducting traditional two-handed phacoemulsification through two relatively small incisions by using a phacoemulsification tip / sleeve with reduced diameter along with a second irrigation tip, with or without an attached manipulation tool.

A method of conducting traditional two-handed phacoemulsification through two relatively small incisions by using a phacoemulsification tip / sleeve with reduced diameter along with a second irrigation tip, with or without an attached manipulation tool.

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided.

A compound having the general formula (I) R1—NH—CH[(CH2)n—NH—C(NH)—NH2]-CO—R2-A-R4; a pharmaceutical composition comprising the compound and use of the compound for the manufacturing of a medicament for the treatment of a disease such as a microbial disease and / or proliferation / stimulation of eukaryotic cells is described.